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R. M. Grant et al. (Special Section on HIV/AIDS: 
Follow the Money, Perspectives, "Whither or wither 
microbicides?", 25 July 2008, p. 532) raise 
provocative points on how candidate microbicides 
are evaluated and selected for testing in 
effectiveness studies, and how microbicide research 
should be redirected for success. The authors make 
valid observations and provide a valuable platform 
for candid discussion of the challenges in 
microbicide research—challenges also germane to 
other HIV prevention research approaches, 
including pre-exposure prophylaxis.  
Product selection: We agree that stringent criteria 
must be applied to the selection of microbicide 
products for testing in effectiveness trials. 
BufferGel, Carraguard, cellulose sulfate, 
PRO2000/5, and SAVVY were selected for 
evaluation early in this decade based on the best 
scientific tools and knowledge then available. Since 
then, testing algorithms and assays have become 
more sophisticated. This evolution and what we are 
learning from current trials are already guiding the 
identification and selection of newer candidates.  
Animal models: The authors recommend preclinical 
studies in Non-Human Primate (NHP) models as 
essential to establishing the biological plausibility of 
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candidate microbicides. As with use of NHP models 
to evaluate HIV vaccines, NHP models for 
microbicides are not yet validated, no consensus 
protocol exists, and the model is subject to 
substantial variability. While NHP studies are critical 
to generating and testing hypotheses, we see them 
as parallel, not primary, streams of evidence 
supporting selection of products for effectiveness 
testing.  
Development of combination approaches: 
Strategies for HIV prevention must consider both 
risk and benefit, a balance that, simply put, differs 
considerably for HIV-infected vis-à-vis -uninfected 
individuals. Development of combination 
approaches to treatment has been critical to the 
improvement of HIV therapies. Uninfected 
individuals who will use drugs for prevention, 
whether applied topically or orally, must have 
assurance that chronic exposure to two or more 
drugs has proved to be not only effective but 
extraordinarily safe. As combination microbicides 
advance in preclinical testing, it will be critical to 
work with regulators on how best to evaluate the 
relative safety and effectiveness of single vs. 
combination approaches for use by HIV-uninfected 
individuals.  
Need for greater coordination: The microbicide field 
has established multiple mechanisms for active 
communication and coordination to ensure that 
knowledge gained from past successes and failures 
informs future decisions. These include the Clinical 
Trials "Quick" Working Group and Microbicide 
Donors Committee, both coordinated by the 
Alliance for Microbicide Development. Despite the 
relative absence of large pharmaceutical companies 
from the microbicide field, new chemical entities 
and formulations, new models, innovative 
approaches to improve adherence, and more 
efficient trial designs are shared through these 
cross-coordination efforts. This is made possible by 
a valuable diversity of funders, including the U.S. 
government (CDC, NIH, USAID), U.K. Department 
for International Development and Medical 
Research Council, and philanthropies such as the 
Bill and Melinda Gates Foundation. Cross-agency 
coordinating functions recently established by the 
NIH Office of AIDS Research should also enhance 
future decision-making.  
"Whither or wither microbicides?" asks the 
microbicide field to contemplate its past and future. 
Some of its recommendations are being 
implemented; others, such as combination 
strategies, are in early stages. We recognize that 
we must pursue only the best scientific leads; 
better integrate basic, behavioral, and clinical 
research; and leverage and deploy human and 
monetary resources efficiently. What we cannot do 
is wait. The need for effective HIV prevention 
methods is too great.  
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